SI-BONE To Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022

Rhea-AI Summary

SI-BONE, Inc. (NASDAQ: SIBN) is set to report its financial results for Q4 and the full year of 2021 on February 28, 2022, after market close. A corresponding conference call will begin at 1:30 PM PT, accessible via phone or webcast. The company specializes in surgical treatments for sacropelvic disorders and has established a significant presence with its iFuse Implant System, used in over 65,000 procedures. SI-BONE continues to leverage its market position to explore additional surgical solutions while ensuring insurance coverage for its procedures.

Positive

• Established market leadership with the iFuse Implant System, used in over 65,000 procedures.
• Insurance payors cover SI joint fusion procedures performed with the iFuse Implant System.

Negative

• None.

SANTA CLARA, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the fourth quarter and full year 2021 after market close on Monday, February 28, 2022. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by dialing (866) 470-1968 for domestic callers or (409) 217-8248 for international callers, using conference ID: 6575191. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. In 2009, SI-BONE introduced the iFuse Implant System for minimally invasive surgery of the SI joint, shown to be a source of pain in 15% to 30% of chronic low back pain. Since then, more than 2,600 surgeons have performed a combined total of more than 65,000 SI joint fusion procedures. A unique body of evidence, supporting the iFuse Implant System, including two RCT’s and over 100 peer reviewed publications, has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System. SI-BONE is leveraging its market leadership position, supported by this proprietary reimbursement advantage, to commercialize other devices intended for surgical treatment of related aspects of the human anatomy. For more information or to join our team, please visit us at www.si-bone.com.

For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2022 SI-BONE, Inc. All Rights Reserved.

Investor Contact:

Matt Bacso, CFA
investors@SI-BONE.com

Media Contact:
Joe Powers
jpowers@si-bone.com

FAQ

When will SI-BONE report its 2021 financial results?

SI-BONE will report its financial results for the fourth quarter and full year 2021 on February 28, 2022, after market close.

What is the significance of the iFuse Implant System to SI-BONE?

The iFuse Implant System is a key product for SI-BONE, addressing a major source of chronic low back pain and has facilitated over 65,000 surgical procedures.

How can investors participate in SI-BONE's earnings call?

Investors can participate by dialing (866) 470-1968 for domestic calls or (409) 217-8248 for international calls, using conference ID: 6575191.

What information will be discussed during the SI-BONE earnings call?

The earnings call will discuss the financial results for Q4 and full year 2021, including revenue, earnings per share, and company outlook.